Register
Community
Overview
Experts
Editors
Fellows
Code of conduct
Company
About Us
FAQs
Privacy Policy
Terms of Use
Careers
Programs
News
News Releases
Press Coverage
Publications
Blog
Contact Us
Sign in
Please select the option that best describes you:
Topics:
Hematologic Malignancies
•
Medical Oncology
•
Myelodysplastic Syndromes
•
Hematology
How do you treat an MDS patient who presents with significant cytopenias who is not a candidate for lenalidomide or luspatercept? How do you initiate an HMA when they are severely neutropenic?
Related Questions
Would you still recommend bone marrow biopsy in an elderly non-transplant eligible patient with mild cytopenias if NGS from peripheral blood indicates MDS mutations?
What hemoglobin level prompts you to start erythropoietin in a patient with low-risk MDS?
Is there an advantage to early therapy with hypomethylating agents for high/very high risk patients with MDS who are not transplant candidates and have only mild cytopenias?
How do you approach a patient with CMML requiring platelet transfusions?
Are you now using luspatercept as your first choice for anemia management in patients with low-risk MDS otherwise appropriate for EPO initiation, regardless of presence of SF3B1 or ringed sideroblasts?
Do you use lenalidomide for patients with MDS with 5q- without other cytogenetic abnormalities but with one or more mutations on NGS?
How would you manage a patient with NLPHL and CKD who relapsed after a long disease free interval (i.e. 7 years) following bendamustine?
What is your approach to MRD testing in the frontline treatment of multiple myeloma?
What is your approach to cancer patients who inquire about alternative or complementary treatments?
How would you treat an elderly male with history of mantle cell lymphoma who relapsed after chemoimmunotherapy and cBTKi w/ multiple co-morbidities including CKD and CHF w/ low EF?